Short term performance context for Globus Medical

With no single headline event driving attention today, Globus Medical (GMED) has been moving quietly, with the share price at $90.46 after a 1.4% decline over the past day and 6% over the past week.

Over the past month the stock is roughly flat, with a small 0.8% gain, while the past 3 months show a 1.9% return. This sets the stage for a closer look at its underlying business metrics.

Looking beyond the recent pullback, Globus Medical’s 1 year total shareholder return of 14.8% and 3 year total shareholder return of 59.8% contrast with a more muted year to date share price return of 3.6%. This suggests momentum has cooled even as longer term holders have still seen solid gains.

If you are comparing Globus Medical with other opportunities in the sector, this could be a good moment to see what our screener is surfacing in healthcare focused AI, including 31 healthcare AI stocks as a starting list of ideas.

With Globus Medical posting steady 1 year and 3 year shareholder returns alongside mid single digit annual revenue and net income growth, the key question now is whether the current US$90.46 price leaves upside on the table or whether the market is already pricing in future growth.

Most Popular Narrative: 15% Undervalued

Globus Medical’s most followed narrative pegs fair value at US$106.40, above the last close at US$90.46, and ties that gap to execution in enabling technologies.

Continued innovation and adoption of robotics, navigation, and minimally invasive procedures including expansion of the ExcelsiusGPS ecosystem, launch of the Excelsius XR headset, and robust product pipeline position Globus to capitalize on healthcare digitization trends, driving higher ASPs, stronger market differentiation, and improved gross margins over time.

Want to see what is built into that valuation gap? This narrative leans on sustained revenue expansion, firmer margins, and a future earnings multiple that assumes the story keeps building.

Result: Fair Value of $106.40 (UNDERVALUED)

However, that upside view still runs into real hurdles, including prolonged sales cycles for robotics and ongoing NuVasive and Nevro integration work that could weigh on margins.

Another View: DCF Signals Less Upside

While the popular narrative sees Globus Medical trading below a fair value of $106.40, our DCF model points to a fair value closer to $83.52, which is below the current $90.46 price. If future cash flows are the real anchor, is the market already a step ahead?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Globus Medical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mixed signals here make it hard to lean fully bullish or cautious, so move quickly, check the details yourself, and weigh 5 key rewards alongside everything you have just read.

Looking for more investment ideas?

If this story has you thinking more broadly about your portfolio, do not stop here. The screener can surface other names that might better fit your goals.

• Target reliable cash generators by scanning companies on our solid balance sheet and fundamentals stocks screener (41 results), pairing financial strength with staying power.
• Spot potential mispricings early by running through the 47 high quality undervalued stocks, where quality businesses show up at prices that may look appealing.
• Build a shortlist of future watchlist candidates using the screener containing 24 high quality undiscovered gems, before they land on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.